Outcome associated with later-line IPI/NIVO
| Patients % (n) | |
| IPI/NIVO | |
| BOR | |
| CR | 7.1 (1/14) |
| PR | 42.9 (6/14) |
| SD | 0 (0/14) |
| PD | 50.0 (7/14) |
| Maintenance therapy (NIVO) | |
| Yes | 35.7 (5/14) |
| No | 64.3 (9/14) |
| PFS | |
| Median (range) | 5.07 (2.43–NA) |
| 1-year rate (%) (95% CI) | 42.9 (23.4 to 78.5) |
| 2-year rate (%) (95% CI) | 26.8 (10.9 to 66.0) |
| OS | |
| Median (range) | NR (3.75–NA) |
| 1-year rate (%) (95% CI) | 64.3 (43.5 to 95.0) |
| 2-year rate (%) (95% CI) | 64.3 (43.5 to 95.0) |
| 3-year rate (%) (95% CI) | 64.3 (43.5 to 95.0) |
| Median follow-up (months) (IQR) | 18.85 (17.63–22.40) |
BOR, best overall response; CR, complete response; IPI/NIVO, ipilimumab plus nivolumab; NA, not available; NIVO, nivolumab; NR, not reached; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial remission; SD, stable disease.